Catalent Inc (CTLT) Stock Overview
USA - NYSE:CTLT - US1488061029 - Common Stock
CTLT Key Statistics, Chart & Performance
The current stock price of CTLT is 63.48 USD. In the past month the price increased by 8%. In the past year, price increased by 44.01%.
CTLT Latest News, Press Relases and Analysis
CTLT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.78 | 776.19B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.61 | 256.13B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.95 | 238.94B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.38 | 231.28B | ||
| MRK | MERCK & CO. INC. | 11.3 | 217.38B | ||
| PFE | PFIZER INC | 7.23 | 139.30B | ||
| SNY | SANOFI-ADR | 11.55 | 124.44B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.36 | 87.16B | ||
| GSK | GSK PLC-SPON ADR | 9.75 | 87.89B | ||
| ZTS | ZOETIS INC | 23.38 | 64.44B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.36 | 44.53B |
Related stock screener links
About CTLT
Company Profile
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 16,900 full-time employees. The company went IPO on 2014-07-31. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. The company also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. The company also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
Company Info
Catalent Inc
14 Schoolhouse Rd
Somerset NEW JERSEY 08873 US
CEO: John R. Chiminski
Employees: 16900
Phone: 17325376200
Catalent Inc / CTLT FAQ
What does Catalent Inc do?
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 16,900 full-time employees. The company went IPO on 2014-07-31. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. The company also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. The company also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
What is the current price of CTLT stock?
The current stock price of CTLT is 63.48 USD.
Does CTLT stock pay dividends?
CTLT does not pay a dividend.
What is the ChartMill rating of Catalent Inc stock?
CTLT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of Catalent Inc (CTLT)?
The PE ratio for Catalent Inc (CTLT) is 288.55. This is based on the reported non-GAAP earnings per share of 0.22 and the current share price of 63.48 USD.
Can you provide the market cap for Catalent Inc?
Catalent Inc (CTLT) has a market capitalization of 11.52B USD. This makes CTLT a Large Cap stock.
CTLT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CTLT. When comparing the yearly performance of all stocks, CTLT is one of the better performing stocks in the market, outperforming 86.78% of all stocks.
CTLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTLT. CTLT may be in some trouble as it scores bad on both profitability and health.
CTLT Financial Highlights
Over the last trailing twelve months CTLT reported a non-GAAP Earnings per Share(EPS) of 0.22. The EPS decreased by -61.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| Debt/Equity | 1.38 |
CTLT Forecast & Estimates
14 analysts have analysed CTLT and the average price target is 64.77 USD. This implies a price increase of 2.03% is expected in the next year compared to the current price of 63.48.
For the next year, analysts expect an EPS growth of 350.55% and a revenue growth 8.33% for CTLT